Belatacept (Nulojix) for Kidney Transplant Rejection Prevention

Belatacept (brand name Nulojix, not Beelith) is a selective costimulation blocker—a fusion protein that binds CD80/86 on antigen-presenting cells, preventing CD28-mediated T-cell activation. It is indicated in combination with other immunosuppressants (mycophenolate mofetil and corticosteroids) for prophylaxis of organ rejection in adult and pediatric (≥13 years) kidney transplant recipients.

Key Features

• Mechanism: Blocks the second signal required for full T-cell activation, offering a non-nephrotoxic alternative to calcineurin inhibitors (tacrolimus, cyclosporine).
• Dosing: Intravenous infusion—more intensive early regimen, then monthly maintenance.
• Monitoring: Requires EBV seropositivity (risk of PTLD in EBV-naïve patients).
• Benefits: Better long-term renal function, cardiovascular/metabolic profile vs. CNI-based regimens.

Belatacept represents a paradigm shift toward preservation of allograft function and reduction of chronic CNI toxicity. Patient selection and adherence to infusion schedule are critical for success.